F-star Describes Evolution Of Its Asset Centric Deal-Making
Executive Summary
F-star CEO John Haurum chats to Scrip about how the UK-based company's deal-making strategy has evolved from F-star Alpha through to F-star Delta.
You may also be interested in...
Syncona Focuses On Creating Commercially Ambitious Businesses
With £1bn under management, patient capital company Syncona Limited reveals its strategy for creating and building companies that will generate reimbursable products for patients.
AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Abalos Raises €12M Series A To Develop Arenavirus-Based Cancer Therapies
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.